Hong Kong Other Utilities Stock News

SEHK:639
SEHK:639Metals and Mining

A Look At Shougang Fushan Resources Group’s Valuation After Lower 2025 Profit Guidance

Shougang Fushan Resources Group (SEHK:639) issued 2025 earnings guidance, flagging profit of HK$600 million to HK$700 million, compared with HK$1,494 million in 2024, as lower clean coking coal prices weigh on results. See our latest analysis for Shougang Fushan Resources Group. The earnings guidance lands after a strong run for investors, with the latest share price at HK$3.34 and a 1 year total shareholder return of 53.95% alongside a 5 year total shareholder return of 194.16%. This...
SEHK:1428
SEHK:1428Capital Markets

A Look At Bright Smart Securities (SEHK:1428) Valuation As Index Inclusion And Stock Connect Eligibility Approach

Bright Smart Securities & Commodities Group (SEHK:1428) is set to join the Hang Seng Composite Index, with the change effective March 9, 2026. This inclusion also paves the way for Shanghai Hong Kong Stock Connect eligibility. See our latest analysis for Bright Smart Securities & Commodities Group. The upcoming index inclusion sits on top of a strong run, with a 90 day share price return of 25% and a 1 year total shareholder return of 247.33% pointing to building momentum rather than fading...
SEHK:867
SEHK:867Pharmaceuticals

Assessing China Medical System Holdings (SEHK:867) Valuation After New Kidney Trial Approval And AI Drug Discovery Deal

China Medical System Holdings (SEHK:867) has drawn fresh attention after Chinese regulators cleared human trials for its CMS-D017 kidney disease therapy, alongside a new AI-focused drug discovery partnership with Insilico Medicine. See our latest analysis for China Medical System Holdings. The recent CMS D017 trial clearance and AI drug discovery tie up come as China Medical System Holdings’ share price sits at HK$15.33, with a 30 day share price return of 9.34% and a 1 year total shareholder...
SEHK:9969
SEHK:9969Biotechs

Assessing InnoCare Pharma (SEHK:9969) Valuation As Its Autoimmune Pipeline Advances Through Key Trial Milestones

InnoCare Pharma (SEHK:9969) has drawn fresh attention after dosing the first patient in a Phase II/III trial of its TYK2 inhibitor soficitinib for chronic spontaneous urticaria, alongside progress across several other dermatology indications. See our latest analysis for InnoCare Pharma. Despite the steady stream of trial updates and the recent IND approval for ICP-538, InnoCare Pharma’s 90 day share price return decline of 14.51% contrasts with a 1 year total shareholder return of 91.23%,...
SEHK:1299
SEHK:1299Insurance

A Fresh Look At AIA Group (SEHK:1299) Valuation After Recent Share Price Moves

What recent performance data suggests about AIA Group (SEHK:1299) AIA Group (SEHK:1299) has drawn investor attention after a 1 day return of 2.55%, alongside a 1 year total return of 53.15% and a 3 year total return of 6.65%. See our latest analysis for AIA Group. That 2.55% 1 day share price return sits against a 7 day share price decline of 4.63% and a 90 day share price gain of 4.84%. The 1 year total shareholder return of 53.15% contrasts with a 5 year total shareholder return decline of...
SEHK:700
SEHK:700Interactive Media and Services

Is Tencent Holdings (SEHK:700) Pricing Reflect Long Term Value After Recent Share Price Slide

If you are wondering whether Tencent Holdings is attractively priced today or already reflects most of its potential, this article will walk you through how its current share price stacks up against several valuation checks. Tencent's share price last closed at HK$532.0, with a 2.8% decline over 7 days, a 13.8% decline over 30 days and a 14.6% decline year to date, while the 1 year return sits at 13.0% and the 3 year return at 45.8%, compared to a 19.6% decline over 5 years. Recent headlines...
SEHK:6682
SEHK:6682Software

Asian Stocks That Might Be Trading Below Their Estimated Value

As global markets navigate the complexities of AI disruption and economic shifts, Asian stocks have shown resilience, with indices like Japan's Nikkei 225 experiencing notable gains. In this environment, identifying undervalued stocks requires a keen eye for companies that demonstrate strong fundamentals and potential for growth amidst changing market conditions.
SEHK:992
SEHK:992Tech

Will Record Q3 Sales and Expanding AI Business Change Lenovo Group's (SEHK:992) Narrative

Lenovo Group recently reported third-quarter 2025/26 results showing record sales of US$22,204.33 million, alongside lower quarterly net income of US$545.54 million, while nine‑month profits edged higher year on year to US$1.39 billion. At the same time, Lenovo highlighted rapid growth in AI‑related revenue, restructured its Infrastructure Solutions Group for long-term AI opportunities, and launched new ThinkSmart–Huddly meeting solutions to deepen its presence in AI‑enabled...
SEHK:2432
SEHK:2432Machinery

Asian Growth Stocks With Strong Insider Ownership

As global markets navigate concerns over AI disruption and fluctuating economic indicators, Asia's stock markets have shown resilience, with Japan experiencing significant gains following political developments and China maintaining steady growth despite deflationary pressures. In this climate of uncertainty, investors often look for companies with strong insider ownership as it can signal confidence in the company's prospects by those who know it best.
SEHK:3696
SEHK:3696Life Sciences

Assessing InSilico Medicine Cayman TopCo (SEHK:3696) Valuation After A Strong Momentum-Driven Share Price Rally

Why InSilico Medicine Cayman TopCo is on investors’ radar InSilico Medicine Cayman TopCo (SEHK:3696) has recently caught attention after a strong share price move, including an 18.3% return over the past week and 33.3% over the past month. See our latest analysis for InSilico Medicine Cayman TopCo. The recent jump in InSilico Medicine Cayman TopCo’s share price, with a 7 day share price return of 18.3% and 30 day share price return of 33.3%, sits within a much stronger year to date share...
SEHK:2507
SEHK:2507Aerospace & Defense

Cirrus Aircraft’s G3 Vision Jet Launch Prompts Fresh Look At Valuation And Growth Expectations

What Cirrus Aircraft’s G3 Vision Jet Launch Means For Shareholders Cirrus Aircraft (SEHK:2507) has just begun delivering its Generation 3 Vision Jet, featuring an expanded seven seat layout, refreshed interior materials, and updated avionics including ATC Datalink and other flight deck refinements. This product launch gives investors a fresh reference point to consider Cirrus Aircraft’s position in personal aviation, in the context of its existing revenue of HK$1,316.235 million and net...
SEHK:6938
SEHK:6938Biotechs

Suzhou Ribo Life Science (SEHK:6938) Valuation Check After Recent Share Price Weakness

Why Suzhou Ribo Life Science Is Drawing Investor Attention Suzhou Ribo Life Science (SEHK:6938) has come onto investors’ radar after a month return of about 8% decline, extending a weaker year to date performance and raising fresh questions about sentiment toward its small nucleic acid drug pipeline. See our latest analysis for Suzhou Ribo Life Science. The latest 1 day share price return of a 5.40% decline, on a last close of HK$70.05, sits against a 7 day share price return of 1.08% and a...
SEHK:9926
SEHK:9926Biotechs

Assessing Akeso (SEHK:9926) Valuation After AK139 Trial Approval And Ivonescimab Breakthrough Designation

Akeso (SEHK:9926) has just received approval in China to start Phase II trials for AK139, a first in class IL-4Ra/ST2 bispecific antibody, targeting seven respiratory and autoimmune conditions. See our latest analysis for Akeso. Investors seem to be weighing Akeso's busy clinical calendar against recent volatility, with a 1 day share price return of 1.54% and 7 day return of 4.36% following the AK139 and ivonescimab updates. The 1 year total shareholder return of 74.92% points to strong...
SEHK:9966
SEHK:9966Biotechs

Assessing Alphamab Oncology (SEHK:9966) Valuation After JSKN003 Phase III Trial Patient Dosing Milestone

Alphamab Oncology (SEHK:9966) has dosed the first patient in its Phase III trial of JSKN003 for HER2-positive advanced colorectal cancer, marking a key milestone for this antibody-drug conjugate following its Breakthrough Therapy Designation in China. See our latest analysis for Alphamab Oncology. The JSKN003 milestone comes after a mixed run in the shares, with a 1-year total shareholder return of 124.81% contrasting with a 30-day share price return decline of 12.74% and longer term 3 and 5...
SEHK:981
SEHK:981Semiconductor

How SMIC’s Q4 Profit and Flat Q1 Margin Outlook Will Impact Semiconductor Manufacturing International (SEHK:981) Investors

Semiconductor Manufacturing International Corporation reported fourth-quarter 2025 results with sales of US$2,488.71 million and net income of US$172.85 million, and later issued first-quarter 2026 guidance indicating sequentially flat revenue and an 18%–20% gross margin range. This combination of solid quarterly profitability and a cautious margin outlook gives investors fresh insight into how SMIC is balancing growth with profitability pressures. Next, we’ll examine how SMIC’s guidance for...
SEHK:1211
SEHK:1211Auto

Assessing BYD (SEHK:1211) Valuation As Shares Rebuild Short Term Momentum

BYD stock performance snapshot BYD (SEHK:1211) has recently seen mixed share performance, with a 0.8% decline over the past day, a 5.9% gain over the past week, and a small pullback over the past month. Over longer periods, BYD shows a 1.0% negative return year to date, an 18.6% negative total return over the past year, and positive total returns across the past 3 and 5 years, highlighting both volatility and staying power. The shares last closed at HK$97.75, with recent annual revenue of...
SEHK:992
SEHK:992Tech

Lenovo Reshapes Infrastructure Group For AI As Shares Trade Below Targets

Lenovo Group (SEHK:992) is restructuring its Infrastructure Solutions Group to place greater emphasis on AI driven offerings. The company is expanding AI centric products and services while dealing with an industry wide crunch in memory chip supply. Management is prioritizing cost savings and new AI enabled hardware and infrastructure solutions to adapt its operations and product mix. For you as an investor, the key point is that Lenovo is reshaping a core infrastructure business around AI...